scholarly journals Surgical Management of Multiple Myeloma and Plasmocytoma of the Spine

2020 ◽  
pp. 054-059
Author(s):  
Evangelisti G ◽  
Pesce E ◽  
Gala R ◽  
Bandiera S ◽  
Tedesco G ◽  
...  
2019 ◽  
Vol 8 (5) ◽  
pp. 59-63
Author(s):  
Rosana Muñoz-Bermúdez ◽  
Eugenia Abella ◽  
Flavio Zuccarino ◽  
Joan Ramon Masclans ◽  
Juan Nolla-Salas

10.14444/7112 ◽  
2020 ◽  
Vol 14 (5) ◽  
pp. 785-794
Author(s):  
HELENA MILAVEC ◽  
NIVETHA RAVIKUMAR ◽  
NICHOLAS L. SYN ◽  
CINNIE YENTIA SOEKOJO ◽  
WEE JOO CHNG ◽  
...  

2019 ◽  
Vol 8 (5) ◽  
pp. 59-63 ◽  
Author(s):  
Rosana Muñoz-Bermúdez ◽  
Eugenia Abella ◽  
Flavio Zuccarino ◽  
Joan Ramon Masclans ◽  
Juan Nolla-Salas

2019 ◽  
Vol 8 (5) ◽  
pp. 82-86
Author(s):  
Rosana Muñoz-Bermúdez ◽  
Eugenia Abella ◽  
Flavio Zuccarino ◽  
Joan Ramon Masclans ◽  
Juan Nolla-Salas

2012 ◽  
Vol 203 (2) ◽  
pp. 127-131 ◽  
Author(s):  
Jared Garrett ◽  
V. Suzanne Klimberg ◽  
Elias Anaissie ◽  
Bart Barlogie ◽  
Richard Turnage ◽  
...  

2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.


2019 ◽  
Vol 4 (5) ◽  
pp. 857-869
Author(s):  
Oksana A. Jackson ◽  
Alison E. Kaye

Purpose The purpose of this tutorial was to describe the surgical management of palate-related abnormalities associated with 22q11.2 deletion syndrome. Craniofacial differences in 22q11.2 deletion syndrome may include overt or occult clefting of the palate and/or lip along with oropharyngeal variances that may lead to velopharyngeal dysfunction. This chapter will describe these circumstances, including incidence, diagnosis, and indications for surgical intervention. Speech assessment and imaging of the velopharyngeal system will be discussed as it relates to preoperative evaluation and surgical decision making. Important for patients with 22q11.2 deletion syndrome is appropriate preoperative screening to assess for internal carotid artery positioning, cervical spine abnormalities, and obstructive sleep apnea. Timing of surgery as well as different techniques, common complications, and outcomes will also be discussed. Conclusion Management of velopharyngeal dysfunction in patients with 22q11.2 deletion syndrome is challenging and requires thoughtful preoperative assessment and planning as well as a careful surgical technique.


2000 ◽  
Vol 111 (4) ◽  
pp. 1118-1121 ◽  
Author(s):  
A. Bellahcene ◽  
I. Van Riet ◽  
C. de Greef ◽  
N. Antoine ◽  
M. F. Young ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document